REPLACE: safety and efficacy of basiliximab in calcineurin inhibitor intolerant long-term kidney transplant recipients treated with mycophenolic acid and steroids

Trial Profile

REPLACE: safety and efficacy of basiliximab in calcineurin inhibitor intolerant long-term kidney transplant recipients treated with mycophenolic acid and steroids

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Basiliximab (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics
  • Acronyms REPLACE
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Oct 2009 Actual end date (1 Dec 2008) and actual patient number (7) added as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top